Company Directory / research

PrivateFor profitresearchMelbourne, Australia
Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy.
Size
11-50 people: larger than 33% of companies with a size listed
Age
11 years old.
Reach
Website ranked #11,510,596 in the world for traffic, about 156 visits a month.
BiotechnologyHealth CareWellness
Funding, as listed
$42M currency not stated
What the source datasets report. We have not watched these rounds ourselves.
Everything the source datasets list about Aravax, field by field. Contact details are held but never shown.
The company
Where
Size and reach
Funding, as listed
About this record
Growth, as the source summarises it
Aravax may be growing as it has successfully raised significant funds in a Series B round, securing US$68 million to advance its peanut allergy therapy. This capital injection is indicative of investor confidence and provides the financial resources necessary for further development and potential commercialization of its treatment. Additionally, the company has been involved in groundbreaking research for a peanut allergy cure, which suggests progress in its core business operations and potential for future revenue streams.
Summaries written by the source dataset, not by us, and not checked.
research in Australia.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 128,574 companies in Australia and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.